Chronic Skin-Specific Inflammation Promotes Vascular Inflammation and Thrombosis  by Wang, Yunmei et al.
Chronic Skin-Specific Inflammation Promotes
Vascular Inflammation and Thrombosis
Yunmei Wang1,2, Huiyun Gao1,2, Candace M. Loyd3, Wen Fu3, Doina Diaconu3, Shijian Liu1,2,
Kevin D. Cooper3,4, Thomas S. McCormick3,4, Daniel I. Simon1,2 and Nicole L. Ward3,4
Patients with psoriasis have systemic and vascular inflammation and are at increased risk for myocardial
infarction, stroke, and cardiovascular death. However, the underlying mechanism(s) mediating the link between
psoriasis and vascular disease is incompletely defined. This study sought to determine whether chronic
skin-specific inflammation has the capacity to promote vascular inflammation and thrombosis. Using the
KC-Tie2 doxycycline-repressible (Dox-off) murine model of psoriasiform skin disease, spontaneous aortic root
inflammation was observed in 33% of KC-Tie2 compared with 0% of control mice by 12 months of age (P¼ 0.04)
and was characterized by the accumulation of macrophages, T lymphocytes, and B lymphocytes, as well as by
reduced collagen content and increased elastin breaks. Importantly, aortic inflammation was preceded by
increases in serum tumor necrosis factor-a, IL-17A, vascular endothelial growth factor, IL-12, monocyte
chemotactic protein-1, and S100A8/A9, as well as splenic and circulating CD11bþLy-6Chi pro-inflammatory
monocytes. Doxycycline treatment of old mice with severe skin disease eliminated skin inflammation and the
presence of aortic root lesion in 1-year-old KC-Tie2 animals. Given the bidirectional link between inflammation
and thrombosis, arterial thrombosis was assessed in KC-Tie2 and control mice; mean time to occlusive
thrombus formation was shortened by 64% (P¼ 0.002) in KC-Tie2 animals; and doxycycline treatment returned
thrombosis clotting times to that of control mice (P¼ 0.69). These findings demonstrate that sustained skin-
specific inflammation promotes aortic root inflammation and thrombosis and suggest that aggressive treatment
of skin inflammation may attenuate pro-inflammatory and pro-thrombotic pathways that produce cardiovas-
cular disease in psoriasis patients.
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INTRODUCTION
Psoriasis is a chronic inflammatory skin disease affecting
between 2.5 and 6 million patients in the United States.
Clinical data have convincingly demonstrated that psoriasis
patients have an increased risk for developing cardiovascular
disease (CVD), including myocardial infarction and stroke
(Gelfand et al., 2006, 2009; Prodanovich et al., 2009; Mehta
et al., 2010, 2011a; Ahlehoff et al., 2011a) and an increased
risk of thromboembolic events (Ahlehoff et al., 2011b).
Psoriasis patients have more established CVD risk factors,
including higher levels of serum cholesterol and triglycerides
coupled with low high-density lipoprotein (Pietrzak et al.,
2009; Toker et al., 2009), elevated pro-inflammatory
mediators (i.e., IL-17, IL-23 (Kryczek et al., 2008) and
S100A8/A9 (Benoit et al., 2006)), and lower levels of anti-
inflammatory mediators such as IL-10 and adiponectin (Kaur
et al., 2008; Takahashi et al., 2008), and these correlate with
disease severity (Boehncke et al., 2011c). Psoriasis is
accompanied by impaired endothelial function (Balci et al.,
2009) and increased subclinical atherosclerosis as measured
by carotid intimal–medial thickness measurements (Balci
et al., 2009), arterial stiffness (Gisondi et al., 2009), and
coronary calcium scores (Ludwig et al., 2007). More recent
work suggests that psoriasis confers an additional 6.2%
absolute risk of a 10-year rate of major adverse cardiac events
compared with the general population (Mehta et al., 2011a).
However, these epidemiological studies do not provide
insight as to the etiology of this elevated risk and rely on
adjusting for confounders such as hyperlipidemia, hyperten-
sion, and diabetes, and thus cannot demonstrate causality.
Common inflammatory cascades have critical roles in the
initiation and maintenance of psoriasis and CVD (Libby,
2002; Lowes et al., 2007; Spah, 2008; Alexandroff et al.,
2009), including activation of antigen-presenting cells and
macrophages, involvement of Th1, Th17, and regulatory
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T cells, and a critical role for IL-12p40 and tumor necrosis
factor-a (TNF-a). Psoriasis patients not only have significant
inflammation in the skin but also have subclinical inflam-
mation in the liver, joints, tendons, and vascular tree
even after adjusting for traditional cardiovascular risk
factors (Mehta et al., 2011b), suggesting that psoriasis itself
predisposes to pro-inflammation pathways independent of
traditional risk factors. Others have suggested a more
direct hypothesis that psoriasis-initiated skin and systemic
inflammation causes insulin resistance, which promotes
endothelial cell dysfunction, subsequent atherosclerosis,
and, ultimately, myocardial infarction or stroke (Boehncke
et al., 2011c).
Despite the epidemiological association between psoriasis
and CVD, the underlying mechanism(s) mediating the link
between psoriasis and vascular disease is incompletely
defined. Whether localized, chronic cutaneous inflammation
directly promotes vascular inflammation and thrombosis is
unknown. To address this question, we used the KC-Tie2
murine model of psoriasiform skin inflammation, in which
Tie2 transgene expression is confined to keratinocytes and
which recapitulates many characteristics of human plaque
psoriasis (Wolfram et al., 2009; Johnston et al., 2011;
Ostrowski et al., 2011; Swindell et al., 2011; Ward et al.,
2011). We hypothesized that the presence of sustained skin-
confined inflammation would predispose animals to vascular
inflammation and thrombosis.
RESULTS
Lesion characterization
At 12 months of age on a standard chow diet, spontaneous
development of robust aortic root inflammation was observed
in 33% of KC-Tie2 mice with psoriasiform skin disease
compared with 0% of control mice (P¼0. 04) (Figure 1a–d).
Lesion formation, quantified by measuring vessel wall area of
the aortic root at the level of the aortic valve was higher in the
KC-Tie2 mice compared with control mice (325±48 mm2 vs.
221±12 mm2, n¼ 18–19 per group; P¼ 0.04) (Figure 1e). No
lesions were detected in the descending thoracic or
abdominal aorta. Aortic root lesions were also stained with
oil-red O and Sudan IV for lipid deposition. There was no
significant lipid staining in the inflamed aortic roots of
KC-Tie2 mice on a standard chow diet.
Examination of the aortic root revealed significant
accumulation of inflammatory cells (CD45-positive leuko-
cytes; Figure 1f–h) in KC-Tie2 mice (13.5±2.9% CD45-
positive area) compared with control animals (2.5±1.4%,
Po0.001) and affected all layers of the vessel wall. Leukocyte
subset analysis was performed by staining for macrophages
(Figure 1i–k), T cells (Figure 1l–n), and B cells (Figure 1o–q).
Macrophage accumulation was increased 2.8-fold in KC-Tie2
mice (13.8±1.7% Mac-3-positive area) compared with
controls (4.9±1.2%, Po0.0001). The accumulation of both
T cell and B cell in the aortic root was enhanced in KC-Tie2
mice, with a 3.9-fold increase in T cells (12.2±2.0% vs.
3.2±0.7% CD3-positive area, P¼ 0.0004) and a 2.2-fold
increase in B cells (18.4±2.4% vs. 8.3±1.9% B220-positive
area, P¼0.0003).
Examination of the extracellular matrix (ECM) using
trichrome staining revealed decreased collagen content in
the lesions in KC-Tie2 animals compared with the dense
collagen content observed in control mice (Figure 2a–d).
Aortic elastin integrity was investigated by Verhoeff
elastin staining and revealed abundant elastin breaks and
fragmentation in the aortic root lesions of KC-Tie2 mice
(Figure 2e–h).
To verify that transgene expression was limited to the skin,
we performed additional matings between the K5tTA driver
mouse and nuclear LacZ reporter mouse lines, and analyzed
LacZ expression in the skin, spleen, brain, liver, kidney, lung,
heart, and aorta of the of KC-LacZ mice (Supplementary
Figures S1 online). Robust LacZ expression was observed in
the skin with little to no expression in the other tissues
including the aorta. In addition, we verified the absence of
aberrant Tie2 expression in the aortic roots of KC-Tie2 mice
that developed vascular inflammation (Supplementary
Figures S1 online). Taken together, these observations
indicate that chronic, skin-specific inflammation in KC-Tie2
mice promotes the de novo development of aortic root
inflammation and alterations in the ECM.
Systemic inflammation
Biomarkers associated with CVD risk were examined in KC-
Tie2 mice. Serum levels of MCP-1 (1.7-fold; P¼ 0.038), IL-
12p70 (4.3-fold; P¼ 0.048), TNF-a (2.1-fold; P¼ 0.05), IL17a
(4.4-fold; P¼0.038), and vascular endothelial growth factor
(1.6-fold; P¼0.02) were all elevated in KC-Tie2 mice
compared with age-matched littermate controls (Figure 3a).
The expression of the pro-inflammatory mediator S100A8/A9
(myeloid related protein-8/14, MRP-8/14) was also increased
in the skin and serum of KC-Tie2 mice compared with control
mice (Figure 3b).
Total cholesterol, triglyceride, and low-density lipoprotein
cholesterol levels were lower in KC-Tie2 mice compared
with control mice, although not all reached statistical
significance. Reduced high-density lipoprotein levels were
observed in KC-Tie2 mice (Figure 3c).
Specific monocyte subpopulations (i.e., Ly-6Chi) have
been implicated in monocyte/macrophage vessel wall
infiltration and atherosclerotic lesion formation. Therefore,
we evaluated splenic and circulating CD11bþLy-6Chi
monocytes in KC-Tie2 mice at 6 months of age before aortic
root inflammation. Splenic CD11bþLy-6Chi monocyte levels
were increased by 42% (P¼0.009) in KC-Tie2 compared
with control mice (Figure 3d). Similar results were observed
in circulating blood (Supplementary Figures S2 online).
Inflammation and thrombosis
Given the bidirectional link between inflammation and
thrombosis, we assessed arterial thrombosis in KC-Tie2 mice
compared with control mice using a photochemical (Rose
Bengal-green light laser) carotid artery injury model, which
produces thrombosis because of local free-radical release and
oxidative endothelial cell injury (Watson et al., 1985; Falati
et al., 2004; Furie and Furie, 2005). The time to occlusive
thrombus formation was shortened significantly in KC-Tie2
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mice compared with control mice (n¼ 9–10; 19±3 vs.
53±8minutes, P¼0.002) (Figure 4).
Skin disease remission
To examine whether aggressive targeting of skin inflamma-
tion would reverse the presence of aortic root vascular
lesions, 7-month-old mice with severe skin disease were fed
doxycycline-supplemented food to repress gene expression
and reverse skin disease (Wolfram et al., 2009; Silver et al.,
2011). At 12 months of age, both skin inflammation (data not
shown) and aortic root lesions were eliminated in KC-Tie2
mice (0%; n¼ 9; Figure 5a–f).
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Figure 1. Aortic roots develop spontaneous vascular inflammation by 1 year of age in KC-Tie2 animals and not in control animals. Aortic roots from
(a, c) control and (b, d) KC-Tie2 animals stained with hematoxylin and eosin (H&E). (e) Quantitation of aortic root vessel wall area demonstrates significant
increases in area in KC-Tie2 mice (n¼19) compared with control littermates (n¼ 18). Immunohistological staining and quantitative analyses of positively (+ve)
stained (f–h) CD45þ , (i–k) Mac-3þ , (l–n) CD3þ , (o–q) and B220þ cells (% positively stained area) within the aortic roots of (f, i, l, o; n¼ 5) representative control
and (g, j, m, p; n¼ 5) KC-Tie2 mice with vascular inflammation reveal significant increases in inflammatory cell infiltrates. *Po0.05 versus control animals.
Bar¼100 mm.
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To assess the effect of skin disease remission on occlusive
thrombosis formation, KC-Tie2 and control animals were fed
doxycycline-supplemented food for 6 weeks, and then pho-
tochemical carotid artery injury was performed to produce
thrombosis. Doxycycline treatment returned KC-Tie2 throm-
bosis clotting times to control mouse levels (n¼ 10; 31±8
controlsþdoxycycline vs. 36±9 KC-Tie2 þ doxycycline;
P¼0.69; Figure 5g). Control animals treated with doxycy-
cline had slightly shorter clotting times than untreated control
mice; however, this difference was not significant (P¼0.07).
DISCUSSION
In this study, we have identified that sustained skin
inflammation itself is sufficient to promote vascular inflam-
mation and thrombosis. This conclusion is supported by
the following data: (1) KC-Tie2 mice develop aortic root
inflammatory lesions; (2) collagen content is decreased and
elastin fragmentation is increased in the aortic root of KC-
Tie2 mice; (3) pro-inflammatory cytokines and chemokines
are increased in the skin and peripheral blood of KC-Tie2
mice that precede the development of aortic root inflamma-
tory lesions; (4) inflammatory CD11bþ Ly-6Chi monocytes
are elevated in KC-Tie2 animals before lesion development;
(5) thrombotic occlusion time after photochemical carotid
injury is shortened in KC-Tie2 mice; and (6) aortic root
inflammatory lesions and thrombosis clotting times signifi-
cantly improve in KC-Tie2 mice following skin disease
repression.
Psoriasis patients have an increased risk for developing
CVD, including myocardial infarction and stroke. However,
the high prevalence of standard CVD risk factors in patients
with psoriasis required statistical adjustments for the con-
founding effects of these variables in psoriasis epidemiologi-
cal studies (Gelfand et al., 2006, 2009; Mehta et al., 2010,
2011a). Thus, the question of whether inflammatory hyper-
plastic disease confined to the skin has the capacity to
directly cause vascular inflammation and thrombosis was,
heretofore, unknown. It was highly beneficial to use a murine
model of psoriasis that recapitulates many aspects of the
human disease (Wolfram et al., 2009; Johnston et al., 2011;
Ostrowski et al., 2011; Swindell et al., 2011; Ward et al.,
2011), including the characteristic histological, immunologi-
cal, and pro-inflammatory cytokine profiles, as well as
disease attenuation/clearance in response to clinically
efficacious therapeutics, but without standard CVD risk
factors (i.e., hyperlipidemia, hypertension, diabetes, obesity)
to elucidate the effect of the disease itself. Using this model,
our findings provide direct evidence linking skin inflamma-
tion with the development of vascular inflammation, as well
as an increased propensity for arterial thrombosis after
endothelial redox-mediated injury.
Chronic inflammation and pro-inflammatory cytokines
have significant roles in the pathogenesis of both psoriasis
and vascular disease. Evidence suggests that psoriasis and
CVD share common pathogenic features (Spah, 2008;
Alexandroff et al., 2009), including immunological processes,
inflammatory cytokine profiles, and the presence of local and
systemic inflammatory markers (Ross, 1999; Libby, 2002;
Hansson, 2005; Lowes et al., 2007; Spah, 2008; Alexandroff
et al., 2009; Federman et al., 2009; Gisondi and Girolomoni,
2009; Boehncke et al., 2011c). Activation of these inflam-
matory cells (dendritic cells, macrophages and T cells)
together with the release of pro-inflammatory cytokines
(e.g., TNF-a, IFN-g, IL-12) contribute to the development of
psoriatic lesions (Lowes et al., 2007) and have a major role in
the development and vulnerability of atherosclerotic plaque
(Ross, 1999; Libby and Simon, 2001; Libby, 2002; Hansson,
2005). The idea that similar mechanisms underlie the
development of both psoriasis and CVD is supported by the
findings of others (Shepherd et al., 2004) such that sustained
IL-1 signaling, accomplished via genomic deletion of the IL-
1RA, resulted in three types of strain-dependent inflammatory
changes, including a psoriasiform dermatitis in ear skin,
arthritis-like inflammation in the joints, and large-vessel
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Figure 2. Anatomical characterization of aortic arch lesions. Aortic roots
from (a, c, e, g) control and (b, d, f, h) KC-Tie2 animals stained with (a–d)
trichrome or (e–h) Verhoeff–van Gieson elastin reveal decreased expression of
collagen in trichrome-stained aortic arch tissue from KC-Tie2 mice and
increases in the numbers of elastin breaks in Verhoeff–van Gieson
elastin-stained aortic root tissues. Bar¼ 100mm.
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arterial inflammation. However, this experimental approach
resulted in increased IL-1 signaling throughout the body.
The KC-Tie2 mouse has confined gene expression of
the membrane-bound Tie2 receptor to keratinocytes; thus,
our findings provide experimental evidence that keratinocyte
signaling and cell–cell interactions within the cutaneous
environment can initiate inflammation capable of causing
vascular inflammatory foci formation in distant vessels,
perhaps as a result of changes in both circulating proin-
flammatory cytokines and leukocytes (CD11bþ Ly-6Chi
monocytes). KC-Tie2 mice have higher levels of pro-
inflammatory cytokines and chemokines, as well as of splenic
and circulating pro-inflammatory CD11bþLy-6Chi monocytes,
which precede and are associated with the development of
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Figure 3. Aortic root vascular inflammation develops in the presence of elevated systemic inflammation and monocytosis, and independent of lower lipid
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www.jidonline.org 2071
Y Wang et al.
Psoriasis, Vascular Inflammation, and Thrombosis
vascular inflammation and disease, and occur independent of
changes in lipids. The clinical relevance of our observations
in KC-Tie2 mice is supported by highly sensitive, metabolic
imaging (i.e., (18F)-fluorodeoxyglucose positron emission
tomography-computed tomography, FDG-PET/CT) in psor-
iasis patients showing concomitant aortic inflammation.
Coupled with our thrombosis observations, this suggests that
elevated levels of inflammation could potentially be used to
predict poor outcomes and adverse cardiovascular events in
patients with psoriasis. Taken together, these findings provide
insight into skin-specific contributions underlying prior
epidemiological reports that psoriasis patients are at an
increased risk for myocardial infarction, stroke, venous
thromboembolism, and cardiovascular mortality (Gelfand
et al., 2006, 2009; Prodanovich et al., 2009; Mehta et al.,
2010, 2011a; Ahlehoff et al., 2011a, b).
There is increasing evidence for an important link between
inflammation and thrombosis. Leukocyte–platelet interactions
induce bidirectional signals that amplify pro-inflammatory
and pro-thrombotic cellular responses (Libby and Simon,
2001). Activated platelets and platelet-released mediators
(e.g., PDGF and PAF) activate leukocytes, thereby enhancing
their responses such as chemotaxis, reactive oxygen species
generation, phagocytosis, and pro-coagulant activity (Bazzo-
ni et al., 1991; Nagata et al., 1993; Kuijper et al., 1997;
Lindemann et al., 2001). Conversely, activated leukocytes
induce platelet activation as evidenced by increased platelet
P-selectin and activated glycoprotein IIb/IIIa expression
(Li et al., 2000). Psoriasis patients have elevated P-selectin,
the levels of which correlate with disease severity (Garbar-
aviciene et al., 2010). The most compelling observation of
this study relates to the finding that occlusive thrombus
formation was shortened significantly in KC-Tie2 compared
with control mice and supports recent epidemiological reports
demonstrating that psoriasis patients had higher incident rates
of venous thromboembolism (Ahlehoff et al., 2011b). Acute
myocardial infarction typically results from atherosclerotic
plaque disruption or superficial endothelial cell erosion and
thrombosis that cause coronary arterial occlusion (Davies and
Thomas, 1985; Farb et al., 1996). Yet, molecular events that
precede acute myocardial infarction in patients with psoriasis
remain uncertain. This mouse model provides valuable clues
addressing this gap area in at-risk psoriasis patients. For
example, both S100A8/A9 (Figure 3b) and MPO (data not
shown), which are elevated in the skin and peripheral blood
of KC-Tie2 mice and psoriasis patients (Benoit et al., 2006),
have been implicated in acute coronary syndromes, includ-
ing unstable angina and myocardial infarction (Baldus et al.,
2003; Healy et al., 2006; Morrow et al., 2008).
Interestingly, most of the literature examining psoriasis and
CVD report increases in either cardiovascular risk factors
100
Cl
ot
tin
g 
tim
e 
(m
inu
te
s)
90
80
70
60
50
40
30
20
10
Control
Co
nt
ro
l
KC-Tie2
KC
-T
ie
2
0
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and KC-Tie2 mice following Rose Bengal laser treatment. (b) Note the
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Figure 5. Repressing skin inflammation improves aortic root lesions and thrombosis clotting times. Seven-month-old KC-Tie2 mice (n¼ 9) and control
littermates (n¼9) were treated with doxycycline to repress transgene expression and to reverse skin inflammation. Aortic roots from (a, c, e) representative
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(diabetes, hypertension, hyperlipidemia) (Gelfand et al.,
2006; Prodanovich et al., 2009; Mehta et al., 2010), changes
in CVD surrogate markers (MPO, adiponectin, S100A8/A9)
(Benoit et al., 2006; Kaur et al., 2008; Takahashi et al., 2008),
or indirect measures of CVD via endothelial function, carotid
artery intimal-medial thickness (Balci et al., 2009), and
stiffness measurements (Gisondi et al., 2009). KC-Tie2
animals have elevated systemic inflammation independent
of obesity, hyperglycemia, and hyperlipidemia, demonstrat-
ing that skin inflammation alone can elicit systemic levels of
inflammation critical for inflammatory lesion formation in the
aortic root and promotion of thrombosis. Our observation of
localized inflammation in the aortic root is consistent with
the anatomical localization of aortic inflammation previously
observed in psoriasis patients (Mehta et al., 2011b), and this
focus of inflammation appears to be specific rather than
representative of an overall generalized vascular inflamma-
tory effect affecting all vessels of the body. Moreover, the
location of vascular inflammatory lesions also highly
correlates with sites that develop atherosclerosis in humans.
Whether atherosclerosis is in fact elicited by psoriasis
remains unclear. We cannot rule out the fact that, with time,
these mice would develop atherosclerosis; however, on a
non-athero-susceptible genetic background strain, and con-
sidering the short life span of a mouse, these experiments are
not likely to yield insightful data addressing this issue. Rather,
the usefulness of the murine model lends itself to modeling
experiments whereby variables known to be increased
in psoriasis patients (i.e., dietary choices, very-low-density
lipoprotein levels, ApoB, diabetic state, hypertension) could
be manipulated in KC-Tie2 animals, and the synergistic or
additive effects of vascular inflammation coupled with the
experimental manipulation on atherosclerotic plaque deve-
lopment and thrombosis could be examined.
Our observations of aortic root vascular lesion resolution
and improved thrombosis outcomes following skin-specific
transgene repression provide further evidence demonstrating
that cutaneous inflammation promotes vascular inflammation
and thrombosis and suggest that aggressive treatment of skin
inflammation may attenuate pro-inflammatory and pro-
thrombotic pathways that produce CVD in psoriasis patients.
Although not skin specific, recent prospective reports
document significant improvement in endothelial vasodilator
function (Boehncke et al., 2011a) and CVD biomarker levels
(Boehncke et al., 2011b) in psoriasis patients following 24
weeks of systemic therapeutic treatment.
Evidence linking chronic inflammation to the develop-
ment of vascular inflammation is not limited to psoriasis. For
example, periodontal disease is an important independent
causal risk factor for atherosclerotic disease, including
coronary heart disease and ischemic stroke (DeStefano
et al., 1993; Humphrey et al., 2008). Importantly, periodontal
therapy has been shown to alter gene expression of peripheral
blood monocytes, suggesting that local therapies could have
a systemic anti-inflammatory effect (Papapanou et al., 2007).
Similar to periodontal disease, rheumatoid arthritis is asso-
ciated with increased carotid artery intimal–medial thicken-
ing, as well as increased cardiovascular events independent
of traditional cardiac risk factors. Ongoing prospective
clinical trials are examining the effect of disease-modifying
therapies, such as anti-TNFa, on cardiovascular complica-
tions of rheumatoid arthritis.
The results of our study provide strong evidence of remote,
extravascular tissue inflammation promoting induction of
CVD and suggest that suppression of skin inflammation is a
viable approach worthy of investigation to favorably impact
CVD complications of psoriasis.
MATERIALS AND METHODS
Animals
The KC-specific (K5-tTA) driver line and the TetosTek/Tie2 responder
lines have been described previously (Diamond et al., 2000; Jones
et al., 2001). Matings were performed between the K5tTA line and
the TetosTek/Tie2 line, and offspring were genotyped by PCR using
DNA extracted from ear biopsies as previously described (Wolfram
et al., 2009). We have previously demonstrated that animals
inheriting a single copy of K5tTA and Tetos Tie2 (KC-Tie2
bi-transgenic mice) have B50-fold increase in Tie2 mRNA and
spontaneously develop a psoriasiform skin phenotype (Wolfram
et al., 2009). Male and female KC-Tie2 animals were used in the
current studies, and littermates inheriting one or no transgenes served as
experimental controls. Transgene repression was completed as
previously described (Wolfram et al., 2009; Silver et al., 2011).
All animal protocols were approved by the Case Western Reserve
University institutional animal care and use committee and con-
formed to the American Association for Accreditation of Laboratory
Animal Care guidelines.
Protein analysis
See Supplemental Material online.
Flow cytometry
Four-color flow cytometry was used to stain neutrophils, monocytes,
and macrophages. Cells were incubated with a cocktail of mAbs
against T cells (CD90-PE, 53–2.1), B cells (B220-PE, RA3-6B2), NK
cells (CD49b-PE, DX5 and NK1.1-PE, PK136), neutrophils
(Ly-6G–PE, 1A8), myeloid cells (CD11b-APC, M1/70), and monocyte
subsets (Ly-6C–FITC, AL-21), as described previously (Swirski et al.,
2007; Shi et al., 2008). F4/80 (BM8)-biotin-strep-PerCP, I-Ab (AF6-
120.1)-biotin-strep-PerCP, and CD11c (HL3)-biotin-strep-PerCP
mAbs (BD Biosciences, San Diego, CA) also served to determine
macrophage and dendritic cell differentiation (see also Supplemental
Material online).
Histology and lesion analysis
Mice were perfused transcardially as previously described (Croce
et al., 2009) before dissection of the heart and aorta. For analysis of
the aortic root, the bottom half of the heart was cut off in a plane
parallel to the left and right atria. The top half of heart was
embedded in paraffin after dehydration in ethanol and xylene. Serial
5-mm heart sections were obtained and stained with hematoxylin
and eosin (Sigma, St Louis, MO). Trichrome staining (Sigma) was
performed to visualize collagen. Elastic laminae were visualized
by staining the sections with Verhoeff–van Gieson (Sigma), as
recommended by the manufacturer. Immune cell staining was
performed as described in the Supplemental Material online.
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To quantify the size of aortic root lesions, vessel wall area
(including lesional area, if present) was measured using a computer-
assisted image analysis program (Zeiss Axiovision software, Rel 4.5,
Thornwood, NY).
Photochemical carotid artery thrombosis
Ten-week-old male and female KC-Tie2 transgenic and littermate
control mice were anesthetized by intraperitoneal injection with
sodium pentobarbital (62.5mg kg1) and placed in the supine
position on a dissecting microscope. Animals at this time point
have established skin disease with abundant inflammatory cell
infiltrate (Wolfram et al., 2009; Ostrowski et al., 2011; Ward et al.,
2011). Animals had a midline surgical incision made to expose the
right common carotid artery, and a Doppler flow probe (MC 0.5PSL
Nanoprobe, Model 0.5 VB, Transonic Systems, Ithaca, NY) was
placed under the exposed artery. The probe was connected to a flow
meter (Transonic Systems Model TS420). Flow data were interpreted
with a computerized data acquisition program (Windaq, DATAQ
Instruments, Akron, OH). Rose Bengal at a concentration of
10mgml1 in phosphate-buffered saline was then injected into
the tail vein to administer a dose of 50mg kg1. Following Rose
Bengal injection, the mid portion of the common carotid artery
was illuminated with a 1.5-mW green-light laser source (540 nm;
Melles Griot, Carlsbad, CA) at a distance of 5 cm from the artery.
Blood flow was monitored continuously from the onset of injury.
The time to occlusion, determined only after the vessel remained
closed with a cessation of blood flow for 20minutes, was
recorded.
Statistical analysis
All data are represented as mean±SEM. Between-group compar-
isons were analyzed using either a Student’s t-test or a Mann–
Whitney U-test, and statistical significance was defined as Po0.05.
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